3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Neoplasms
6
Frailty
4
Lymphoma
3
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Prostate Cancer Cured
1
Neoplasms, Plasma Cell
1
Multiple Myeloma
1
Lung Neoplasms
1
HER2 Positive Breast Carcinoma
1
Colorectal Neoplasms
1
Interventions
Cyclophosphamide
62
Dexamethasone
60
Melphalan
54
Peripheral Blood Stem Cell Transplantation
49
Bortezomib
40
Busulfan
39
fludarabine phosphate
34
Filgrastim
32
Lenalidomide
30
Thalidomide
27
Tacrolimus
25
Antilymphocyte Serum
23
Radiotherapy
22
Mycophenolic Acid
17
Methotrexate
17
Prednisone
15
Etoposide
15
sargramostim
14
Cyclosporine
14
fludarabine
12
Methylprednisolone
11
Granulocyte Colony-Stimulating Factor
11
Calcium Dobesilate
11
Whole-Body Irradiation
10
Doxorubicin
9
Carmustine
9
pomalidomide
8
Vincristine
8
Interferon-alpha
8
Cord Blood Stem Cell Transplantation
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplasms, Plasma Cell
×
Geriatric Assessment
×
Clear all
NCT05101759
2024-09-25
LYMPHOLD
University Hospital, Toulouse
Phase NA
Completed
100 enrolled